Crossmark

Predictors for patient satisfaction of a single intra-articular injection of crosslinked hyaluronic acid combined with mannitol (HANOX-M-XL) in patients with temporomandibular joint osteoarthritis. Results of a prospective open-label pilot study (HAPPYMINI-ARTEMIS trial)

Crossref DOI link: https://doi.org/10.1186/s12891-022-05352-3

Published Online: 2022-04-27

Published Print: 2022-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Baron, Dominique

Baron, Hugo

Baerer, Catherine

Bodere, Céline

Conrozier, Thierry
License Information

Text and Data Mining valid from 2022-04-27

Version of Record valid from 2022-04-27
More Information

Article History

Received: 4 February 2022

Accepted: 18 April 2022

First Online: 27 April 2022

Declarations

:

: The ARTEMIS study was performed in accordance with appropriate guidelines. The patient informed consent form and the protocol that complied with the requirements of the International Conference on Harmonization (ICH) were reviewed and approved by the CCTIRS. The study was registered on August 13, 2018 under ClinicalTrials.gov Identifier NCT03627429.

: Not applicable.

: D. Baron received fees from LABRHA for board member services and from LCA and Expansciences for speaker services.H. Baron does not declare any conflicts of interest.C. Baraer does not declare any conflicts of interest.C. Bodéré does not declare any conflicts of interest.T. Conrozier received fees from LABRHA, SANOFI, MEDAC and FIDIA for scientific, speaker and/or board member services.

Document is current

Any future updates will be listed below